Search

Press Release: News on Red Cells and Iron presented at the 18th Congress of the European Hematology Asscociation in Stockholm June 13-16, 2013

Recent evidence suggests that these congenital anaemias are caused by molecular abnormalities in the transport of iron and other molecules and a deeper understanding of these mechanisms may lead to a better knowledge of the normal development of the red…

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Read more

Press release: Theme of the Year and Patient Advocacy - 18th Congress of EHA - European Hematology Association

This year for the first time, the EHA congress program is complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.

Read more

Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

Report on first EHA-SWG Scientific Meeting

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.

Read more

José Carreras Award handed out at the 17th Congress of EHA

He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.

Read more

Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

Read more